share_log
Breakings ·  Dec 16 20:30
Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (Gbs)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment